Table 13.

Clinical outcomes of polymer paclitaxel and paclitaxel therapy in patients with advanced gastric cancer.

Treatment	N	Response rate	Median TTP	Median OS	1-year survival	Ref.
		(%)	(months)	(months)	(%)
Polymer-paclitaxel Therapeutics
Genexol-PM/cisplatina	35	46	4.9	13.8	50.2	[2]
NK105b	56	25	-	10.2	-	[54]
Paclitaxel Therapeutics
Paclitaxelc	60	23	-	-	43	[53]
Paclitaxel/carboplatind	27	33	-	7.5	23	[51]
Paclitaxel/cisplatine	49	43	5.9	11.2	40.4	[52]

^aPatients with advanced gastric cancer, PS 0-1 on ECOG scale, received Genexol® (paclitaxel) at 175 mg/m² i.v. infusion over period of 3 h, followed by cisplatin 75 mg/m² i.v. infusion, every 21 days, with hypersensitivity reaction to pre-medications;

^bPatients with gastric cancer, received NK105 (paclitaxel) at 150 mg/m² i.v. infusion over period of 30 min, every 21 days;

^cPatients with advanced gastric cancer, PS 0-2 on ECOG scale, paclitaxel at 210 mg/m² i.v. infusion over period of 3 h, every 21 days, with hypersensitivity reaction to pre-medications;

^dPatients with advanced gastric cancer, PS 0-2 on ECOG scale, paclitaxel at 200 mg/m² i.v. infusion over period of 3 h, followed by carboplatin AUC 5, every 21 days, with hypersensitivity reaction to pre-medications;

^ePatients with advanced gastric cancer, PS 0-2 on ECOG scale, paclitaxel at 100 mg/m² i.v. infusion over period of 1 h, followed by cisplatin 30 mg/m², every 7 days, with hypersensitivity reaction to pre-medications